Stratos Wealth Partners LTD. Has $53,000 Stock Position in Amarin Co. plc (NASDAQ:AMRN)

Stratos Wealth Partners LTD. reduced its stake in Amarin Co. plc (NASDAQ:AMRN) by 17.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,854 shares of the biopharmaceutical company’s stock after selling 13,150 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Amarin were worth $53,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Foundations Investment Advisors LLC acquired a new position in Amarin in the third quarter valued at approximately $25,000. Creative Planning lifted its position in shares of Amarin by 66.4% during the 2nd quarter. Creative Planning now owns 17,285 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 6,900 shares during the period. MML Investors Services LLC grew its holdings in Amarin by 129.1% in the third quarter. MML Investors Services LLC now owns 27,721 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 15,620 shares during the period. Quantbot Technologies LP bought a new stake in Amarin in the first quarter valued at $31,000. Finally, Sei Investments Co. acquired a new position in shares of Amarin during the fourth quarter valued at about $33,000. 22.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Amarin in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Amarin has an average rating of “Hold” and a consensus target price of $1.08.

Amarin Trading Up 2.4 %

NASDAQ AMRN opened at $0.92 on Thursday. The company has a fifty day simple moving average of $1.02 and a 200 day simple moving average of $0.93. Amarin Co. plc has a 12-month low of $0.65 and a 12-month high of $1.49. The company has a market cap of $376.63 million, a P/E ratio of -6.55 and a beta of 1.98.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. The firm had revenue of $74.71 million during the quarter, compared to analysts’ expectations of $72.46 million. Sell-side analysts predict that Amarin Co. plc will post -0.14 EPS for the current year.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.